Parashar Neha, Gupta Rashmi J, Gupta Divya, Siroha Alka, Garg Sandeep, Kumar Suresh
Department of Clinical Pathology, Lok Nayak Hospital, New Delhi, India.
Department of Community Medicine, Maulana Azad Medical College, New Delhi, India.
Indian J Pathol Microbiol. 2025 Apr 1;68(2):349-353. doi: 10.4103/ijpm.ijpm_365_24. Epub 2024 Sep 2.
The recent pandemic caused by the newly identified virus, SARS-Cov-2 is associated with thromboembolic events. Patients infected with COVID-19 have been found to have thrombocytopenia. A decrease in platelet count may be caused by increased destruction and consumption of platelets or by decreased production of platelets in the bone marrow. Immature platelet fraction (IPF) is a new platelet parameter that is an indicator for peripheral destruction and consumption of platelets.
To assess the immature platelet fraction (IPF) in patients infected with COVID-19.
The present study is a retrospective study where secondary data obtained from previous laboratory records of COVID-positive patients admitted at a tertiary care hospital in Delhi from 4 January to 4 February 2022 was analyzed. Sixty-eight COVID-positive patients were included. Platelet parameters included from the automated hematology analyzer Mindray were platelet count, mean platelet volume (MPV), immature platelet fraction (IPF), and platelet large cell ratio (P-LCR). Data was analyzed using SPSS Version 25. A P value less than 0.05 was considered statistically significant.
In the present study mild thrombocytopenia was noted in 40% of the patients infected with COVID-19 admitted to the hospital. The median platelet count in these patients was found to be 91,000/mm 3 (64,000-1,31,000). Low platelet count was associated with a significantly higher IPF, MPV, PDW, P-LCR, and a significantly lower PCT as compared to patients infected with COVID-19 with normal platelet count. There was a significant increase in IPF with a decrease in platelet count ( P value < 0.05). A significant increase in IPF was noted with an increase in MPV and P-LCR ( P value < 0.05).
The present study suggests that thrombocytopenia in patients infected with COVID-19 may probably be due to peripheral destruction and consumption of platelets.
最近由新发现的病毒SARS-CoV-2引起的大流行与血栓栓塞事件有关。已发现感染新型冠状病毒肺炎（COVID-19）的患者存在血小板减少症。血小板计数下降可能是由于血小板破坏和消耗增加或骨髓中血小板生成减少所致。未成熟血小板比率（IPF）是一种新的血小板参数，是血小板外周破坏和消耗的指标。
评估感染COVID-19患者的未成熟血小板比率（IPF）。
本研究为回顾性研究，分析了2022年1月4日至2月4日在德里一家三级护理医院收治的COVID阳性患者的既往实验室记录中的二级数据。纳入68例COVID阳性患者。迈瑞全自动血液分析仪检测的血小板参数包括血小板计数、平均血小板体积（MPV）、未成熟血小板比率（IPF）和血小板大细胞比率（P-LCR）。使用SPSS 25版进行数据分析。P值小于0.05被认为具有统计学意义。
在本研究中，40%入住医院的感染COVID-19患者出现轻度血小板减少症。这些患者的血小板计数中位数为91,000/mm³（64,000 - 131,000）。与血小板计数正常的COVID-19感染患者相比，血小板计数低与IPF、MPV、血小板分布宽度（PDW）、P-LCR显著升高以及血小板压积（PCT）显著降低相关。随着血小板计数下降，IPF显著升高（P值<0.05）。随着MPV和P-LCR升高，IPF显著升高（P值<0.05）。
本研究表明，感染COVID-19患者的血小板减少症可能是由于血小板的外周破坏和消耗所致。
